GSK2857916
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for GSK2857916, covering 2019-09-26 to 2022-12-23. Get the full timeline:
Most recent: Clinical Trial Update: Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]